Public drug programs have a rather bizarre context. Government announcements appear to be based on the assumptions that drug prices are too high, pharmaceutical firms profits are excessive, new products usually represent minor improve at inappropriately high prices, and that there are other therapies that provide equally effective care at a lower cost. Based on the fuzzy logic of the current public drug benefit programs the twenty myths identified by Dr. John Bachynsky need to be examined.